News from sangamo biosciences, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-NMS:SGMO,NASDAQ-NMS:SHPGY,RICS:SHP.L,RICS:SHPGY.O,LSE:SHP)

Feb 09, 2016, 16:03 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Reports Fourth Quarter And Full Year 2015 Financial Results

 Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year...

Feb 08, 2016, 07:00 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I

 Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA)...

Feb 04, 2016, 16:03 ET
Sangamo BioSciences, Inc. (PRNewsFoto/Sangamo BioSciences, Inc.) (PRNewsFoto/)

Sangamo BioSciences Announces Presentation At The Leerink Partners 5th Annual Global Healthcare Conference

 Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president...

Feb 02, 2016, 16:03 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Announces Fourth Quarter And Full Year 2015 Conference Call And Webcast

Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the company will release its fourth...

Jan 11, 2016, 07:00 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Highlights 2016 Catalysts at the 34th Annual J.P. Morgan Healthcare Conference

 Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that Edward Lanphier, Sangamo's president and...

Jan 05, 2016, 16:03 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference

 Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president...

Dec 11, 2015, 07:00 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies

 Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the...

Dec 07, 2015, 07:00 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Presents Data At The 2015 American Society Of Hematology Meeting Highlighting ZFP Therapeutic® Programs For Hemophilia And Hemoglobinopathies

 Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced the presentation of data from its ZFP...

Dec 01, 2015, 07:00 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has...

Nov 23, 2015, 16:05 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Announces Presentation At The 2015 Piper Jaffray Healthcare Conference

Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and...

Nov 11, 2015, 16:05 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Announces Presentation At The Jefferies Autumn 2015 Global Healthcare Conference

 Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in therapeutic genome editing, announced today that Geoffrey Nichol, M.B., Ch.B., Sangamo's...

Nov 09, 2015, 11:49 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Announces Publication Of Improved Method For Efficient Targeted Integration In Hematopoietic Stem Cells And T-cells

 Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced today the publication in Nature Biotechnology of...

Nov 05, 2015, 16:05 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences To Present Data From ZFP Therapeutic Programs At Annual Meeting Of The American Society Of Hematology

Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced today that non-human primate data from its proprietary...

Oct 28, 2015, 16:05 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Reports Third Quarter 2015 Financial Results

 Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its third quarter 2015 financial results and accomplishments. For the third quarter...

Oct 21, 2015, 16:02 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Announces Third Quarter 2015 Conference Call and Webcast

Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that the company will release its third quarter 2015 financial results after the market...

Sep 30, 2015, 16:02 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Announces Presentation At The 2015 Stem Cell Meeting On The Mesa

Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in therapeutic genome editing, announced today that Elizabeth Wolffe, Ph.D., Sangamo's vice...

Sep 21, 2015, 07:00 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Reports Updated Clinical Data from ZFP Therapeutic® Program for HIV/AIDS at the 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy

 Sangamo BioSciences, Inc. (Nasdaq: SGMO) presented data demonstrating sustained functional control of viral load in the absence of...

Sep 10, 2015, 07:00 ET
Sangamo BioSciences, Inc.

Sangamo Announces Unanimous Recombinant DNA Advisory Committee (RAC) Approval Of ZFP Therapeutic Phase 1 Study Protocol For First In Vivo Genome Editing Application

 Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced unanimous approval by the National Institutes of...

Sep 09, 2015, 16:02 ET
Sangamo BioSciences, Inc.

Sangamo BioSciences Announces Presentation At The 2015 Morgan Stanley Global Healthcare Conference

Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress...

Sep 02, 2015, 07:00 ET
Sangamo BioSciences, Inc.

Sangamo and Shire Restructure Collaboration to Accelerate Development of ZFP Therapeutics® for the Treatment of Hemophilia and Huntington's Disease

Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire plc...